Tiagabine

Tiagabine

File:Tiagabine.svg
Clinical data
Pregnancy category	B3 (Au), C (U.S.)
Routes of administration	Oral
ATC code	N03AG06 (WHO)
Legal status
Legal status	POM (UK), ℞-only (U.S.)
Pharmacokinetic data
Bioavailability	90%
Protein binding	96%
Metabolism	Hepatic (CYP450 system)
Elimination half-life	7-9 hours
Excretion	Fecal and renal
Identifiers
IUPAC name (3S)-1-[4,4-bis(3-methylthiophen-2-yl)but-3-enyl] piperidine-3-carboxylic acid
CAS Number	115103-54-3
PubChem CID	60648
DrugBank	APRD00344
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C20H25NO2S2
Molar mass	375.55 g/mol

Tiagabine (IPA: Template:IPA) is an anti-convulsive medication produced by Cephalon Inc. and marketed under the brand name Gabitril. The medication is also used in the treatment for panic disorder as are a few other anticonvulsants.

Though the exact mechanism by which tiagabine exerts its effect on the human body is unknown, it does appear to operate as a selective GABA reuptake inhibitor.

Side effects

Tiagabine's most common side effects include confusion, difficulty speaking clearly/stuttering, mild sedation, and in doses over 8 mg, a tingling sensation (paraphasia) in the body's extremities, particularly the hands and fingers.

External links

• Gabitril (manufacturer's website)